$0.407
+0.005 (+1.12%)Al cierre
- Máximo
- 0.425
- Apertura
- 0.402
- Precio medio ponderado por volumen
- 0.41
- Volumen
- 122.17K
- Capitalización
- —
- Mínimo
- 0.391
- Importe
- 49.79K
- EV/EBITDA, TTM
- 0.00
Rocket One Inc. is an artificial intelligence (AI) semiconductor infrastructure company. The Company is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic artificial intelligence (AI) chip technology designed for radiation-tolerant, energy-constrained environments such as low-earth orbit, deep-space platforms, and defense systems. It operates through two segments, which include Biopharmaceutical and AI semiconductor infrastructure. It is also focused on a nanomagnetic matrix multiplier, Skyrmion Spintronic memory, and Swarm Stage AI. The Company's biotechnology pipeline includes HT-001, HT-KIT, HT-ALZ, and its glial cell line derived neurotrophic factor (GDNF)-based metabolic program. The HT-001 is used to treat epidermal growth factor receptor (EGFR)-induced skin disorders. The HT-KIT drug is used to treat the receptor tyrosine kinase KIT in mast cells.
Análisis de IA of Rocket One Inc (RKTO)
VenderRocket One Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $0.41, which is down 70.11% year-to-date. The RSI is at an extremely low 17.995, indicating oversold conditions but also potential further declines. The company has reported negative net income for multiple quarters, with a recent loss of $3,832,651 in Q2 2026, and a forward P/E ratio of 0 suggests that earnings are not expected to improve in the near term. The main risk is the ongoing negative sentiment in the market, as evidenced by a 5-day change of -16.48% and a 20-day change of -37.39%.
Métricas de valoración
Cronología de eventos
Noticias
9.011-03PRnewswireHoth Concludes Phase 2a Trial Early Due to Positive Interim Results
8.510-13PRnewswireRocket One Launches SKYMRAM Program for Next-Gen Memory
8.510-06PRnewswireRocket One Signs Patent License Agreement with Air Force for Counter-UAS Technology
8.510-06NewsfilterRocket One Signs Patent License Agreement with Air Force for Drone Technology
8.509-22NASDAQ.COMRocket One Acquires Tracer Drone Technologies to Enhance AI and Drone Capabilities
Preguntas frecuentes sobre RKTO, respondidas por Alphio AI
Rocket One Inc. is an artificial intelligence (AI) semiconductor infrastructure company. The Company is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic artificial intelligence (AI) chip technology designed for radiation-tolerant, energy-constrained environments such as low-earth orbit, deep-space platforms, and defense systems. It operates through two segments, which include Biopharmaceutical and AI semiconductor infrastructure. It is also focused on a nanomagnetic matrix multiplier, Skyrmion Spintronic memory, and Swarm Stage AI. The Company's biotechnology pipeline includes HT-001, HT-KIT, HT-ALZ, and its glial cell line derived neurotrophic factor (GDNF)-based metabolic program. The HT-001 is used to treat epidermal growth factor receptor (EGFR)-induced skin disorders. The HT-KIT drug is used to treat the receptor tyrosine kinase KIT in mast cells. It operates in the Healthcare sector.
Rocket One Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $0.41, which is down 70.11% year-to-date. The RSI is at an extremely low 17.995, indicating oversold conditions but also potential further declines. The company has reported negative net income for multiple quarters, with a recent loss of $3,832,651 in Q2 2026, and a forward P/E ratio of 0 suggests that earnings are not expected to improve in the near term. The main risk is the ongoing negative sentiment in the market, as evidenced by a 5-day change of -16.48% and a 20-day change of -37.39%.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.